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Abstract: Since recombinant proteins are widely used in industry and in research, the need 
for their low-cost production is increasing. Escherichia coli is one of the best known and 
most often used host organisms for economical protein production. However, upon over-
expression,  protein  aggregates  called  inclusion  bodies  (IBs)  are  often  formed.  Until 
recently  IBs  formation  represented  a  bottleneck  in  protein  production  as  they  were 
considered as deposits of inactive proteins. However, recent studies show that by choosing 
the appropriate host strain and designing an optimal production process, IBs composed 
from properly folded and biologically active recombinant proteins can be prepared. Such 
active protein particles can be further used for the isolation of pure proteins or as whole 
active protein particles in various biomedical and other applications. Therefore interest in 
understanding the mechanisms of their formation as well as their properties is increasing. 
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1. Introduction 
The need for low-cost protein production is increasing as the use of proteins is expanding to various 
areas;  from  research  to  a  range  of  commercial  applications  in  pharmaceutical,  chemical  and  food 
industry, cosmetics as well as biomedical applications (e.g., tissue cultures) and diagnostics. Bacterial 
host systems for recombinant protein production are still very attractive, as they are usually genetically 
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well-characterized having a large number of cloning vectors and mutant host strains available and they 
grow rapidly at high density on inexpensive substrates. It is difficult to decide which combination of 
host  organism-promoter  system  would  be  the  best  for  specific  recombinant  protein  production; 
therefore this still has to be optimized for each product individually.  
Since  Escherichia  coli  have  all  the  above  described  advantages  [1]  and  the  laboratory  strains  are 
regarded as GRAS (Generally Recognized As Safe) organisms, it is still one of the most commonly used 
bacterial host system, not only on laboratory scale use, but also for production of therapeutic proteins [2–5]. 
However, during recombinant protein production in E. coli, proteins often tend to aggregate into 
protein  particles  called  inclusion  bodies  (IBs).  Until  recently,  IBs  were  considered  as  deposits  of 
misfolded and inactive proteins and represented bottleneck in recombinant protein production. Therefore 
many  pharmaceutically  interesting  proteins  have  been  disregarded  for  commercialization  [6]. 
Nevertheless, the latest studies on protein aggregation have shown that protein aggregation into IBs 
does not necessarily imply protein inactivation [7–10] thus studies on protein aggregation has become 
an important subject in many fields, including biology, medicine and biotechnology [11]. This article 
gives an overview on the latest trends in recombinant protein production in E. coli, their aggregation 
and the possible applications of such protein particles (IBs). 
2. E. coli and Recombinant Protein Production 
E.  coli  is  one  of  the  most  widely  used  hosts  for  the  production  of  recombinant  proteins. 
Nevertheless,  choosing  an  optimal  expression  system  is  vital  for  an  efficient  protein  production 
process and is often dependant on recombinant protein itself. There are many different E. coli strains 
and vector systems, however B strains, such as BL21, combined with pET vectors, became popular 
due to their efficiency in recombinant protein production [2,12]. Because of well controlled promoters, 
this  bacterial  factory  enables  high  recombinant  protein  production  yields  (up  to  50%  of  total  cell 
proteins). It proved to be a very efficient system also for the production of active protein particles 
called non-classical IBs (ncIBs) [7,13–15]. 
However, as recombinant protein production represents stress for the host cell and thus the whole 
cell machinery has to adapt to an over-expression of foreign protein, quality product can only be 
produced when the whole bioprocess is optimized [15]. 
Therefore in addition to the host organism, a production media should also be optimized and quality 
inoculum  prepared  for  the  reproducibility  of  the  production  process.  Addition  of  some  essential 
microelements  to  the  basic  LB  media  enables  higher  accumulation  of  recombinant  proteins  [16]. 
Furthermore,  lowering  the  cultivation  temperature  was  proven  to  effectively  limit  the  in  vivo 
aggregation of recombinant proteins [17], hence higher amounts of soluble proteins are formed [18] 
and the quality of the proteins is improved, including the ones trapped inside IBs [10,13,14,19,20]. 
Suboptimal  growth  temperatures  slow  down  all  the  cell  processes,  including  transcription  and 
translation [17] thus proteins have more time to fold properly. The extended time period between 
synthesis and deposition, as well as rapidly exceeded solubility of target protein, results in aggregation 
of better folded proteins [20,21].  
While satisfactory protein yields could be achieved in the shake flask culture, extremely high yields 
could only be obtained by high cell density fermentation, using finely tuned expression systems [22]. Int. J. Mol. Sci. 2011, 12  8277 
 
 
Yet strong production of recombinant proteins and thus unusually high transcription rates could result 
in a stressful situation for the host cell [23] that has a negative impact on productivity and protein  
quality [24]. Therefore a fragile balance between high culture density and high protein yield versus 
high protein quality should be maintained for optimal results. 
3. Protein Aggregation and IBs Formation 
The aim of recombinant protein production is to yield high amounts of the desired proteins. As a 
result the host organism is often forced to produce proteins above the cells physiological capacity. 
Upon over-expression, a high amount of proteins are constantly formed that cannot be simultaneously 
processed  by  the  protein  synthesis  machinery,  thus  the  quality  control  system  is  activated  [25]. 
Additionally, E. coli has simple protein folding machinery, which lacks post–translational modifications. 
Due  to  the  reducing  potential  of  the  E.  coli  cytoplasmic  redox  state,  the  production  of  proteins 
possessing  more  disulfide  bonds  still  remains  a  challenge.  The  combination  of  all  these  factors, 
together with the exceeded solubility of over-expressed recombinant protein leads to the aggregation of 
recombinant proteins, which often gives rise to IBs formation.  
IBs were for a long time understood as inert deposits of misfolded and inactive proteins in some 
way separated from the cellular repair mechanism. However, it is now known that protein aggregation 
into IBs is reversible [26] and dependent on the physiological state of the host organism. IBs are very 
dynamic structures that are continuously formed in the host cell and simultaneously the proteins are 
also released from them and refolded or degraded by the cell repair mechanisms [27]. 
Since  protein  aggregates  represented  an  obstacle  in  recombinant  protein  production,  various 
mechanisms  that  would  enable  production  of  soluble  proteins  in  bacteria  were  studied.  Yields  of 
soluble protein expression can be increased by chaperone co-expression [28], fusion of target protein 
with suitable fusion tags [29], choosing appropriate host strain and promoter system or modifying the 
cultivation conditions (e.g., growth temperature, media composition) [17]. However, studies showed, 
that protein solubility does not imply protein activity, as large amount of the proteins found soluble in 
the cytoplasm can be biologically inactive [7,8]. 
The formation of protein aggregates is a self-assembly process in bacterial cells. As there is no 
compartmentalization, proteins are simultaneously synthesized on multiple locations in the bacterial 
cytoplasm and various transitional folding states of the target protein are formed (Figure 1). Some of 
the folding intermediates that fail to fold into a native conformation are immediately degraded by the cells’ 
repair mechanisms, while others aggregate into smaller proto-aggregates (“soluble aggregates”) [30]. 
During this nucleation, predominantly target recombinant protein is incorporated into the proto-aggregates 
by  cross-molecular  stereospecific  interactions,  while  the  other  non-homologous  cellular  (and  even 
recombinant) proteins are excluded from this seeding events [25]. This leads to the rapid growth of 
proto-aggregates that are later fused together in an IB that continually grows further to form the final 
IB as depicted in Figure 2 [21,31]. Inside the IB, the network of partially folded proteins is formed and 
studies show that this network has an amyloid-like structure [32]. Properly folded protein precursors 
are  trapped  into  this  network  (Figure  3)  [21].  A  similar  self-assembly  process  of  amyloid-like 
structures has also been observed in yeasts [33], fungi [34], plants [35] and can be observed in many Int. J. Mol. Sci. 2011, 12 
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Figure 2. Protein folding and aggregation in 
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Figure  3.  Network  of  proteins  inside  IB.
misfolded/partially folded proteins
The protein network is loosely connected at neutral pH. The transfer of IBs into acidic pH 
(around 4) results in strong contraction of the protein network
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Protein folding and aggregation in E. coli. Many proteins fail to fold to the native 
conformation during protein synthesis, therefore various transitional folding intermediates 
are  present  in  the  cell  together  with  properly  folded  proteins.  Cells’  quality  control 
machinery  maintains  kinetic  equilibrium  between  soluble  and  aggregated  forms  of  the 
protein.  Soluble  fraction  is  composed  of  single  protein  molecules  as  well  as  soluble 
aggregates. Inside the soluble aggregates, properly folded proteins are also trapped. Soluble 
aggregates are further aggregated into insoluble aggregates called inclusion bodies. The 
process in reversible and it is controlled by the cell quality control mechanism.
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Figure 4. IB observed with a scanning electron microscope. The IBs washed with water (b) 
and additionally rapidly washed in mild detergent (a) [7]. It seems that IBs are composed 
of small proto-aggregates imbedded into a cotton-like amorphous matrix (a). However, the 
amorphous matrix fills the spaces both among and inside the proto-aggregates which gives 
the IB a porous surface (b). 
 
3. Properties of Properly Folded Protein Aggregates 
The shape and size of IBs is very much dependant on the host bacterial strain. So the IBs were 
found to be spherical [7,38], ellipsoidal [31,39], cylindrical [40,41] and even tear-shaped [42] ranging 
in size form 50–700 nm [7,42].  
There is usually one and only rarely two IBs present in the bacterial cell. So after the bacterial cell 
division, when two cells emerge, IB is present in only one cell while the other cell is empty. Recent 
study showed that IB is actively translocated to the cell pole before cell division and in this manner 
aggregated proteins can be removed from bacterial population in nature [37]. In bacterial culture where 
protein production is artificially induced, production of recombinant proteins in the vacant cells begins 
de novo and a new IB is formed (Figure 1), while the IBs that remain in the cells after cell division 
grow further. Therefore there are various populations of bacterial cells present simultaneously in the 
bacterial culture. 
Thus the shape and size of IBs is dependant not only on the host strain, but also on the time of 
cultivation. Based on our observation in the case of spherical IBs, they form spheres at the beginning 
of cultivation. However, when the IB grows and reaches the bacterial cell wall and it can no longer 
grow in one direction it starts to form the cylinder. Therefore, the population of IBs after long-term 
cultivation  (24  h)  is  very  diverse  as  some  of  the  IBs  in  the  population  have  been  growing  for  
24 h and have formed large cylinders that nearly occupy the whole bacterial cell, ranging from smaller 
cylinders and large spheres all the way to small spheres that are just beginning to form (Figure 5).  
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Figure  5.  The diverse population of IBs after 24 h production. The protein production 
starts immediately after the inducer is added to the medium. Therefore some of the IBs in 
the population have been growing for 24 h and formed cylinders that occupy almost the 
entire cell space. In contrast, other IBs started growing de novo after each bacterial cell 
division. Therefore the whole range from small spherical IBs, that have been formed in the 
final hour of cultivation, to large spheres that have been growing for several hours all the 
way to the cylinders are simultaneously present in the one sample. 
 
The activity of proteins inside IBs varies significantly, depending on the target protein as well as the 
production conditions. The active protein particles, ncIBs, are composed from significant amounts of 
properly folded and biologically active proteins, trapped into the network of misfolded proteins. Thus 
they possess some interesting properties that can be exploited for various biotechnological, as well as 
biomedical, applications. Such ncIBs are extremely fragile and soluble in contrast to classical IBs. 
They  are  soluble  in  mild  detergents  and  even  in  buffers  usually  used  to  wash  and  store  classical  
IBs [7,13]. Therefore optimization of isolation and washing process is necessary in order not to impair 
the structure of IBs or the protein trapped inside [40,43]. It was shown that sonication, often used for 
bacterial cell disruption, can damage the structure of ncIBs. Furthermore, the structure of properly 
folded proteins trapped inside ncIBs can also be destroyed and significant proportion of biologically 
active protein can thus be lost [40]. 
Another  interesting  property  of  IBs  (classical  as  well  as  non-classical)  is  their  irreversible 
contraction at low pH. It seems that the high proton concentration in acidic buffers induces a change in 
the network of unfolded/partially folded proteins and this leads to a strong contraction of the protein 
network and formation of more compact IBs [21]. Consequently the solubility of contracted ncIBs is 
greatly reduced. While at neutral pH the protein network is loosely bound, the extraction of native-like 
precursor molecules as well as some still soluble proteins having biologically inactive conformations is 
easy (Figure 3a) [8,13]. However, the contraction of protein network in acidic pH traps the properly 
folded precursors into the IB and their extraction prevented (Figure 3b). Thus when soluble ncIBs are 
needed for further applications, the buffers used for washing and storing the IBs should be carefully 
chosen to prevent ncIBs contraction. 
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4. What Can We Learn from Properly Folded Protein Aggregates and How Can We Use Them? 
Understanding protein folding and mechanisms of protein aggregates (IBs) formation in bacteria 
can serve as a model for protein aggregation in higher organisms and help us understand how and why 
human conformational diseases progress [32]. Besides this, understanding the properties of IBs could 
also give us an insight into the properties of protein aggregates formed in mammalian cells. This 
knowledge could serve as a background for identification of novel target sites for the development of 
novel and more efficient treatments for human conformational diseases. 
Furthermore, IBs, formed after over-expression of recombinant proteins in bacteria, are a highly 
pure protein deposit of target recombinant protein as it can represent more than 95% of all protein 
present  inside  the  IBs  [44].  Historically,  IBs  were  considered  as  the  main  obstacle  in  protein 
production while isolating active proteins from IBs represented a great challenge. However, ncIBs 
composed from significant amount of properly folded and biologically active proteins, easily soluble in 
mild detergents, are ideal for protein isolation. Since ncIBs are extremely fragile and soluble, bacterial 
cell  disruption  process  should  be  optimized.  After  bacterial  cell  disruption  ncIBs  are  washed  and 
collected with centrifugation, and the majority of the impurities are removed already in this step. The 
buffers used during cell disruption and for ncIBs washing should also be carefully chosen, not to 
dissolve the IBs [7,13,40,43]. While ncIBs are soluble in mild detergents, recombinant protein can be 
extracted  from  them  in  mild  non-denaturing  conditions  in  biologically  active  form,  therefore  no 
renaturation step is needed. The protein isolation process is thus simplified, less protein specific, more 
cost effective and environment-friendlier [7,13–15,45,46]. Since the need for recombinant proteins is 
constantly increasing, this process could be well exploited in the future. 
In the past few years with the development of nanobiotechnology the field of possible applications 
of  protein  particles  (IBs)  is  broadening  and  protein  micro-  and  nano-particles  are  becoming 
increasingly interesting. The IBs are therefore studied for various biomedical applications [47]. 
As IBs are large protein particles that can easily trigger the immune response, the idea of using the 
whole IBs as a vaccine was tested by several different research groups simultaneously. Successful 
protective immunity was reported for vaccines against several animal diseases (e.g., liver fluke, classical 
swine  fever,  salmonid  rikettsial  septicaemia  …)  [48–50]  as  well  as  against  human  oral  infections 
(gingivitis and periodontitis) [51]. 
Furthermore, IBs composed from a suitable protein (pseudan) can be used as a coating in medical 
tubes to reduce or even inhibit biofilm formation [52]. On the other hand, recent studies showed, that 
IBs can be utilized as a scaffold material in tissue engineering, as they affect the mammalian cell 
attachment and proliferation [39,42,53]. 
However, the protein particles employed in these applications were described as classical, insoluble 
IBs and the activity (proper folding) of the entrapped proteins is not discussed. With the preparation of 
active protein particles, the scope of possible applications is even broader. As a result Nahálka and  
co-workers prepared IBs composed from a wide variety of different biologically active enzymes that 
were  shown  to  act  as  biocatalysts  [54–59]  and  could  also  be  used  for  the  development  of  new 
diagnostic techniques [60]. In addition, soluble ncIBs could also be used as protein delivery system.  
Furthermore, coating of IBs with various coatings was shown to additionally stabilize IBs structure 
and even enhance enzymatic activity of these active protein particles [58,59].  Int. J. Mol. Sci. 2011, 12  8283 
 
 
The field of nanobiotechnology is new and fast evolving, thus predicting various possibilities of IBs 
applications is difficult. However, it could be anticipated that such nanoparticles could be used in the 
development of new treatments and diagnostic techniques in medicine, biomedicine and pharmacology 
as  well  as  biocatalysts  in  various  industries  (cosmetics,  biotechnology,  food  and  chemical  
industry) [47,61,62]. 
5. Conclusion and Perspectives 
Protein  aggregation  into  IBs  has  long  been  considered  as  an  obstacle  in  protein  production  in 
bacteria. However, the knowledge gained during studies of protein aggregation in bacteria could help 
us understand the human progressive conformational diseases that represent a growing problem with 
increased prevalence in an aging society.  
Furthermore,  with  carefully  designed  bioprocess  production  of  active  and  even  soluble  protein 
aggregates  being  possible,  such  aggregates  can  be  used  in  biotechnology  for  the  isolation  of  pure 
recombinant  proteins  and  as  micro-/nanoparticles  in  various  biomedical  and  pharmacological 
applications as well as in other fields.  
As  this  is  still  an  emerging  and  fast  evolving  discipline,  the  protocols  for  production  and 
preparation of protein particles have to be redesigned and carefully optimized. A more thorough and 
systematic study on production and properties of such protein particles is needed in order to enable the 
design of particles with the desired properties (e.g., solubility, biological activity, size, shape…) [62].  
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